Elicio Therapeutics Company
Elicio Therapeutics develops an immuno-tumor vaccine to treat cancer.
Last Funding Date:
2021
Last Funding Type:
Series B
Investors Number:
5
Industry:
Biotechnology, Health Care, Medical, Pharmaceutical, Therapeutics
Founded Date:
2011
Investor Type:
Early Stage Venture
Employee Number:
11-50
Total Funding:
148461801
Headquarters:
Cambridge, Massachusetts, United States
Estimated Revenue:
Less than $1M